Amedisys (AMED) Stock Forecast, Price Target & Predictions
AMED Stock Forecast
Amedisys stock forecast is as follows: an average price target of $143.38 (represents a 47.95% upside from AMED’s last price of $96.91) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
AMED Price Target
The average price target for Amedisys (AMED) is $143.38 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $190.00 to $85.00. This represents a potential 47.95% upside from AMED's last price of $96.91.
AMED Analyst Ratings
According to 10 Wall Street analysts, Amedisys's rating consensus is 'Hold'. The analyst rating breakdown for AMED stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amedisys Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 25, 2024 | Frank Morgan | RBC Capital | $100.00 | $92.16 | 8.51% | 3.19% |
| Jul 06, 2023 | Brian Tanquilut | Jefferies | $90.80 | $91.28 | -0.53% | -6.30% |
| Jan 05, 2023 | - | Leerink Partners | $85.00 | $86.00 | -1.16% | -12.29% |
| Nov 11, 2022 | - | Stephens | $106.00 | $91.78 | 15.49% | 9.38% |
| Jul 26, 2022 | David MacDonald | Truist Financial | $150.00 | $128.18 | 17.02% | 54.78% |
| Jul 03, 2022 | Justin Bowers | Deutsche Bank | $175.00 | $110.82 | 57.91% | 80.58% |
| Apr 29, 2022 | - | Credit Suisse | $182.00 | $131.13 | 38.80% | 87.80% |
| Apr 29, 2022 | - | Raymond James | $180.00 | $128.41 | 40.18% | 85.74% |
| Apr 29, 2022 | - | Leerink Partners | $131.00 | $131.89 | -0.67% | 35.18% |
| Feb 25, 2022 | Matthew Borsch | BMO Capital | $190.00 | $159.90 | 18.82% | 96.06% |
The latest Amedisys stock forecast, released on Mar 25, 2024 by Frank Morgan from RBC Capital, set a price target of $100.00, which represents a 8.51% increase from the stock price at the time of the forecast ($92.16), and a 3.19% increase from AMED last price ($96.91).
Amedisys Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $100.00 |
| Last Closing Price | $96.91 | $96.91 | $96.91 |
| Upside/Downside | -100.00% | -100.00% | 3.19% |
In the current month, the average price target of Amedisys stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amedisys's last price of $96.91. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 29, 2024 | Deutsche Bank | Buy | Hold | Downgrade |
| Jul 01, 2024 | William Blair | - | Market Perform | Downgrade |
| Sep 14, 2023 | Cantor Fitzgerald | Neutral | Neutral | Hold |
| Jan 05, 2023 | SVB Leerink | Market Perform | Market Perform | Hold |
| Nov 11, 2022 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Oct 27, 2022 | Raymond James | Outperform | Market Perform | Downgrade |
| Jul 03, 2022 | Deutsche Bank | Buy | Buy | Hold |
| Jun 21, 2022 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Apr 29, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Apr 29, 2022 | Raymond James | Outperform | Outperform | Hold |
Amedisys's last stock rating was published by Deutsche Bank on Jul 29, 2024. The company Downgrade its AMED rating from "Buy" to "Hold".
Amedisys Financial Forecast
Amedisys Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $556.24M | $552.97M | $556.39M | $562.06M | $557.99M | $557.89M | $545.26M | $559.32M | $553.49M | $564.17M | $537.14M | $550.71M | $544.07M | $485.06M | $491.69M | $500.68M | $494.63M |
| Avg Forecast | $693.78M | $675.76M | $673.39M | $659.18M | $643.88M | $629.88M | $626.02M | $610.32M | $600.23M | $587.98M | $577.49M | $565.38M | $567.40M | $560.23M | $568.18M | $558.96M | $560.56M | $579.31M | $583.12M | $558.82M | $555.18M | $568.27M | $565.48M | $542.50M | $553.34M | $533.67M | $468.41M | $504.84M | $511.58M | $494.23M |
| High Forecast | $707.25M | $688.89M | $686.46M | $671.98M | $656.39M | $642.11M | $638.17M | $622.18M | $611.88M | $598.19M | $588.70M | $576.36M | $575.06M | $567.85M | $579.22M | $569.81M | $571.44M | $590.56M | $593.32M | $568.59M | $564.88M | $578.20M | $575.36M | $551.98M | $563.02M | $543.00M | $476.60M | $513.66M | $520.52M | $502.87M |
| Low Forecast | $682.55M | $664.83M | $662.49M | $648.51M | $633.47M | $619.68M | $615.89M | $600.45M | $590.52M | $578.82M | $568.14M | $556.23M | $559.88M | $551.38M | $558.99M | $549.91M | $551.49M | $569.93M | $573.35M | $549.46M | $545.87M | $558.74M | $556.00M | $533.41M | $544.07M | $524.73M | $460.56M | $496.38M | $503.00M | $485.95M |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 0.97% | 1.00% | 1.00% | 0.96% | 0.96% | 0.98% | 1.01% | 0.97% | 1.00% | 0.99% | 1.00% | 1.02% | 1.04% | 0.97% | 0.98% | 1.00% |
Amedisys's average Quarter revenue forecast for Dec 23 based on 6 analysts is $567.40M, with a low forecast of $559.88M, and a high forecast of $575.06M. AMED's average Quarter revenue forecast represents a 2.01% increase compared to the company's last Quarter revenue of $556.24M (Sep 23).
Amedisys EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $65.47M | $-65.01M | $56.54M | $63.59M | $60.59M | $67.25M | $65.01M | $69.03M | $76.43M | $127.20M | $87.26M | $82.81M | $83.34M | $63.29M | $58.77M | $56.99M | $61.71M |
| Avg Forecast | $86.91M | $84.65M | $84.35M | $82.58M | $80.66M | $78.90M | $78.42M | $76.45M | $75.19M | $73.66M | $72.34M | $70.89M | $71.08M | $70.18M | $71.18M | $64.44M | $70.22M | $73.57M | $73.05M | $58.59M | $69.55M | $71.19M | $70.84M | $80.55M | $69.32M | $66.85M | $58.68M | $53.93M | $64.08M | $61.91M |
| High Forecast | $88.60M | $86.30M | $85.99M | $84.18M | $82.23M | $80.44M | $79.94M | $77.94M | $76.65M | $74.93M | $73.75M | $85.07M | $72.04M | $71.13M | $72.56M | $77.33M | $71.58M | $88.28M | $74.32M | $70.30M | $70.76M | $72.43M | $72.08M | $96.66M | $70.53M | $68.02M | $59.70M | $64.71M | $65.21M | $62.99M |
| Low Forecast | $85.50M | $83.28M | $82.99M | $81.24M | $79.35M | $77.63M | $77.15M | $75.22M | $73.97M | $72.51M | $71.17M | $56.71M | $70.14M | $69.07M | $70.02M | $51.56M | $69.08M | $58.85M | $71.82M | $46.87M | $68.38M | $69.99M | $69.65M | $64.44M | $68.16M | $65.73M | $57.69M | $43.14M | $63.01M | $60.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | -0.91% | 0.88% | 0.91% | 0.82% | 0.92% | 1.11% | 0.99% | 1.07% | 1.80% | 1.08% | 1.19% | 1.25% | 1.08% | 1.09% | 0.89% | 1.00% |
6 analysts predict AMED's average Quarter EBITDA for Dec 23 to be $71.08M, with a high of $72.04M and a low of $70.14M. This is 8.57% upper than Amedisys's previous annual EBITDA (Sep 23) of $65.47M.
Amedisys Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $25.96M | $-43.98M | $25.25M | $31.72M | $25.64M | $29.58M | $31.67M | $34.01M | $45.01M | $80.15M | $49.87M | $45.15M | $71.98M | $34.67M | $31.80M | $27.66M | $34.13M |
| Avg Forecast | $42.70M | $44.50M | $49.92M | $41.52M | $40.90M | $42.17M | $49.83M | $38.37M | $38.48M | $38.59M | $39.09M | $34.56M | $34.10M | $35.65M | $36.09M | $31.42M | $32.13M | $43.32M | $40.65M | $28.56M | $38.88M | $45.14M | $55.04M | $46.03M | $48.53M | $41.93M | $26.87M | $29.18M | $30.60M | $29.58M |
| High Forecast | $43.78M | $45.62M | $51.18M | $42.57M | $41.93M | $43.23M | $51.08M | $39.34M | $39.45M | $46.04M | $40.08M | $41.47M | $40.32M | $43.57M | $37.00M | $37.70M | $32.94M | $51.98M | $41.57M | $34.27M | $39.76M | $46.17M | $56.29M | $55.24M | $49.63M | $42.88M | $27.48M | $35.01M | $31.30M | $30.26M |
| Low Forecast | $41.80M | $43.56M | $48.87M | $40.65M | $40.04M | $41.28M | $48.78M | $37.56M | $37.67M | $32.50M | $38.27M | $27.65M | $30.49M | $31.35M | $35.33M | $25.13M | $31.46M | $34.65M | $39.76M | $22.85M | $38.03M | $44.16M | $53.84M | $36.83M | $47.47M | $41.02M | $26.28M | $23.34M | $29.94M | $28.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | -1.22% | 0.80% | 0.99% | 0.59% | 0.73% | 1.11% | 0.87% | 1.00% | 1.46% | 1.08% | 0.93% | 1.72% | 1.29% | 1.09% | 0.90% | 1.15% |
Amedisys's average Quarter net income forecast for Dec 23 is $34.10M, with a range of $30.49M to $40.32M. AMED's average Quarter net income forecast represents a 31.34% increase compared to the company's last Quarter net income of $25.96M (Sep 23).
Amedisys SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $192.98M | - | $194.56M | $193.43M | $188.34M | $187.82M | $184.47M | $184.85M | $178.93M | $175.22M | $172.24M | $175.60M | $179.62M | $156.34M | $156.74M | $156.06M | $154.71M |
| Avg Forecast | $181.15M | $176.45M | $175.83M | $172.12M | $168.12M | $164.47M | $163.46M | $159.36M | $156.72M | $153.53M | $150.79M | $201.28M | $148.15M | $146.28M | $148.36M | $182.98M | $146.37M | $172.22M | $152.26M | $166.35M | $144.96M | $148.38M | $147.65M | $158.99M | $144.48M | $139.35M | $122.31M | $143.81M | $133.58M | $129.05M |
| High Forecast | $184.67M | $179.87M | $179.24M | $175.46M | $171.39M | $167.66M | $166.63M | $162.46M | $159.77M | $156.19M | $153.72M | $241.54M | $150.15M | $148.27M | $151.24M | $219.58M | $149.21M | $206.66M | $154.92M | $199.62M | $147.50M | $150.97M | $150.23M | $190.79M | $147.01M | $141.78M | $124.44M | $172.58M | $135.91M | $131.30M |
| Low Forecast | $178.22M | $173.59M | $172.98M | $169.33M | $165.40M | $161.80M | $160.81M | $156.78M | $154.19M | $151.13M | $148.35M | $161.03M | $146.19M | $143.97M | $145.96M | $146.39M | $144.00M | $137.77M | $149.71M | $133.08M | $142.53M | $145.89M | $145.18M | $127.19M | $142.06M | $137.01M | $120.26M | $115.05M | $131.34M | $126.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | - | 1.06% | 1.32% | 1.09% | 1.23% | 1.11% | 1.28% | 1.21% | 1.19% | 1.08% | 1.22% | 1.29% | 1.28% | 1.09% | 1.17% | 1.20% |
Amedisys's average Quarter SG&A projection for Dec 23 is $148.15M, based on 6 Wall Street analysts, with a range of $146.19M to $150.15M. The forecast indicates a -23.23% fall compared to AMED last annual SG&A of $192.98M (Sep 23).
Amedisys EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.80 | $-1.35 | $0.78 | $0.98 | $0.79 | $0.91 | $0.97 | $1.04 | $1.38 | $2.46 | $1.52 | $1.38 | $2.20 | $1.07 | $0.98 | $0.86 | $1.06 |
| Avg Forecast | $1.29 | $1.35 | $1.51 | $1.26 | $1.24 | $1.28 | $1.51 | $1.16 | $1.16 | $1.17 | $1.18 | $1.02 | $1.03 | $1.08 | $1.09 | $0.88 | $0.97 | $1.22 | $1.23 | $1.12 | $1.18 | $1.37 | $1.67 | $1.43 | $1.47 | $1.27 | $0.81 | $0.97 | $0.93 | $0.90 |
| High Forecast | $1.32 | $1.38 | $1.55 | $1.29 | $1.27 | $1.31 | $1.55 | $1.19 | $1.19 | $1.39 | $1.21 | $1.05 | $1.22 | $1.32 | $1.12 | $0.91 | $1.00 | $1.25 | $1.26 | $1.14 | $1.20 | $1.40 | $1.70 | $1.46 | $1.50 | $1.30 | $0.83 | $0.99 | $0.95 | $0.92 |
| Low Forecast | $1.26 | $1.32 | $1.48 | $1.23 | $1.21 | $1.25 | $1.48 | $1.14 | $1.14 | $0.98 | $1.16 | $1.00 | $0.92 | $0.95 | $1.07 | $0.87 | $0.95 | $1.19 | $1.20 | $1.09 | $1.15 | $1.34 | $1.63 | $1.40 | $1.44 | $1.24 | $0.80 | $0.95 | $0.91 | $0.88 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.74% | -1.24% | 0.88% | 1.01% | 0.65% | 0.74% | 0.87% | 0.88% | 1.01% | 1.48% | 1.07% | 0.94% | 1.73% | 1.32% | 1.01% | 0.93% | 1.18% |
According to 6 Wall Street analysts, Amedisys's projected average Quarter EPS for Dec 23 is $1.03, with a low estimate of $0.92 and a high estimate of $1.22. This represents a 28.97% increase compared to AMED previous annual EPS of $0.80 (Sep 23).
Amedisys Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HCSG | Healthcare Services Group | $11.14 | $17.33 | 55.57% | Hold |
| SGRY | Surgery Partners | $31.00 | $47.50 | 53.23% | Buy |
| AMED | Amedisys | $96.91 | $143.38 | 47.95% | Hold |
| EHAB | Enhabit | $8.10 | $10.25 | 26.54% | Hold |
| OPCH | Option Care Health | $31.99 | $38.00 | 18.79% | Buy |
| INNV | InnovAge | $5.99 | $6.80 | 13.52% | Hold |
| ACHC | Acadia Healthcare Company | $78.23 | $84.89 | 8.51% | Buy |
| EHC | Encompass Health | $93.25 | $93.17 | -0.09% | Buy |
| ADUS | Addus HomeCare | $130.13 | $123.00 | -5.48% | Buy |
| UHS | Universal Health Services | $232.56 | $208.47 | -10.36% | Hold |
| PNTG | Pennant Group | $34.52 | $30.67 | -11.15% | Buy |
| ENSG | Ensign Group | $152.73 | $114.25 | -25.19% | Buy |
AMED Forecast FAQ
Is Amedisys a good buy?
No, according to 10 Wall Street analysts, Amedisys (AMED) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 40.00% of AMED's total ratings.
What is AMED's price target?
Amedisys (AMED) average price target is $143.38 with a range of $85 to $190, implying a 47.95% from its last price of $96.91. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amedisys stock go up soon?
According to Wall Street analysts' prediction for AMED stock, the company can go up by 47.95% (from the last price of $96.91 to the average price target of $143.38), up by 96.06% based on the highest stock price target, and down by -12.29% based on the lowest stock price target.
Can Amedisys stock reach $150?
AMED's highest twelve months analyst stock price target of $190 supports the claim that Amedisys can reach $150 in the near future.
What are Amedisys's analysts' financial forecasts?
Amedisys's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.51B (high $2.56B, low $2.47B), average EBITDA is $314.44M (high $320.55M, low $309.35M), average net income is $171.26M (high $175.58M, low $167.65M), average SG&A $655.41M (high $668.14M, low $644.8M), and average EPS is $5.18 (high $5.31, low $5.07). AMED's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.7B (high $2.75B, low $2.66B), average EBITDA is $338.49M (high $345.07M, low $333.01M), average net income is $178.64M (high $183.15M, low $174.89M), average SG&A $705.54M (high $719.25M, low $694.13M), and average EPS is $5.41 (high $5.54, low $5.29).
Did the AMED's actual financial results beat the analysts' financial forecasts?
Based on Amedisys's last annual report (Dec 2022), the company's revenue was $2.22B, which missed the average analysts forecast of $2.28B by -2.57%. Apple's EBITDA was $256.44M, missing the average prediction of $275.42M by -6.89%. The company's net income was $118.61M, missing the average estimation of $144.66M by -18.01%. Apple's SG&A was $754.06M, beating the average forecast of $637.19M by 18.34%. Lastly, the company's EPS was $3.65, missing the average prediction of $4.53 by -19.51%. In terms of the last quarterly report (Sep 2023), Amedisys's revenue was $556.24M, missing the average analysts' forecast of $560.23M by -0.71%. The company's EBITDA was $65.47M, missing the average prediction of $70.18M by -6.72%. Amedisys's net income was $25.96M, missing the average estimation of $35.65M by -27.17%. The company's SG&A was $192.98M, beating the average forecast of $146.28M by 31.93%. Lastly, the company's EPS was $0.8, missing the average prediction of $1.08 by -25.83%